Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study

BackgroundReplacement therapy for congenital adrenal hyperplasia (CAH) in childhood includes hydrocortisone and, in salt-wasting forms, addition of fludrocortisone. Immediate-release hydrocortisone often fails to adequately suppress early morning 17-hydroxyprogesterone (17OHP) levels. Hydrocortisone...

Descripció completa

Dades bibliogràfiques

Autors principals:	Erwin Lankes, Levin Wiebelt, Kathrin Bettina Helge, Dirk Schnabel, Peter Kühnen, Oliver Blankenstein, Uta Neumann
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-07-01
Col·lecció:	Frontiers in Endocrinology
Matèries:	17-hydroxyprogesterone children congenital adrenal hyperplasia disease-control growth hydrocortisone modified-release capsules
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fendo.2026.1854737/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!